BEAM:NSD-Beam Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 66.14

Change

-0.74 (-1.11)%

Market Cap

USD 4.14B

Volume

0.98M

Average Target Price

USD 100.86 (+52.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-2.81 (-1.84%)

USD61.31B 102.33 81.58
VRTX Vertex Pharmaceuticals Incorpo..

+1.67 (+0.79%)

USD55.06B 20.27 14.23
REGN Regeneron Pharmaceuticals, Inc

+10.03 (+1.98%)

USD54.03B 14.44 11.17
BNTX BioNTech SE

-5.34 (-2.87%)

USD47.83B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.34 (+0.78%)

USD38.01B 55.82 39.93
BGNE BeiGene, Ltd

-3.87 (-1.24%)

USD27.16B N/A N/A
SGEN Seagen Inc

-0.06 (-0.04%)

USD26.27B 40.39 34.48
RPRX Royalty Pharma plc

-0.40 (-0.99%)

USD24.64B 22.60 15.13
GMAB Genmab A/S

+0.37 (+1.02%)

USD24.15B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BEAM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.70% 31% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.70% 31% F 15% F
Trailing 12 Months  
Capital Gain 300.12% 97% A+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 300.12% 97% A+ 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 70.99% 84% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.99% 84% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 144.56% 16% F 10% F
Risk Adjusted Return 49.11% 75% C 69% D+
Market Capitalization 4.14B 91% A- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 85% B 95% A
Price/Book Ratio 16.33 11% F 9% F
Price / Cash Flow Ratio -43.24 91% A- 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -112.32% 23% F 10% F
Return on Invested Capital -73.83% 29% F 11% F
Return on Assets -27.30% 46% F 14% F
Debt to Equity Ratio 2.16% 72% C- 85% B
Technical Ratios  
Short Ratio 7.02 34% F 18% F
Short Percent 17.70% 9% F 10% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector